Voloridge Investment Management
RXRX icon

Voloridge Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Voloridge Investment Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-359,434
Closed -$1.82M – 1355
2025
Q2 		$1.82M Buy
+359,434
New +$1.77M 0.01% 962
2024
Q4 		– Sell
-973,583
Closed -$6.42M – 1348
2024
Q3 		$6.42M Buy
+973,583
New +$6.98M 0.02% 720
2024
Q2 		– Sell
-660,969
Closed -$6.59M – 1354
2024
Q1 		$6.59M Buy
660,969
+76,014
+13% +$847K 0.02% 578
2023
Q4 		$5.77M Sell
584,955
-269,440
-32% -$1.92M 0.02% 586
2023
Q3 		$6.54M Buy
+854,395
New +$8.52M 0.03% 576
2023
Q2 		– Sell
-50,834
Closed -$339K – 1536
2023
Q1 		$339K Buy
+50,834
New +$403K ﹤0.01% 1271
2022
Q3 		– Sell
-55,266
Closed -$450K – 1594
2022
Q2 		$450K Sell
55,266
-272,369
-83% -$1.82M ﹤0.01% 1309
2022
Q1 		$2.35M Sell
327,635
-50,082
-13% -$532K 0.01% 891
2021
Q4 		$6.47M Buy
+377,717
New +$7.11M 0.04% 623

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Voloridge Investment Management's RXRX Position: Q3 2025 in Review

Voloridge Investment Management sold out of Recursion Pharmaceuticals (RXRX) in Q3 2025, closing a stake of 359,434 shares — an estimated $1.82M sold.

Voloridge Investment Management first reported a position in RXRX in Q4 2021 and held it in 9 quarters. The position peaked at $6.59M in Q1 2024. 322 funds tracked by Wall St. Rank hold RXRX as of Q3 2025.

  • Voloridge Investment Management reported no remaining Recursion Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Voloridge Investment Management sold 359,434 Recursion Pharmaceuticals shares in Q3 2025, an estimated $1.82M.
  • Voloridge Investment Management first reported a position in Recursion Pharmaceuticals in Q4 2021 and held it in 9 quarters.
  • Voloridge Investment Management's Recursion Pharmaceuticals position peaked at $6.59M in Q1 2024.
  • 322 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2025.

Based on Voloridge Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.